Workflow
泓德医疗创新混合发起式A：2025年上半年利润179.63万元 净值增长率24.37%
Sou Hu Cai Jing·2025-09-05 02:25

Core Viewpoint - The AI Fund Hongde Medical Innovation Mixed Initiation A (012481) reported a profit of 1.7963 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.1578 yuan, and a net asset value growth rate of 24.37% [2] Fund Performance - As of September 3, the fund's net asset value growth rate over the past three months was 35.71%, ranking 11 out of 138 comparable funds; over the past six months, it was 54.91%, ranking 45 out of 138; and over the past year, it was 85.29%, ranking 25 out of 136 [5] Investment Strategy - The fund manager stated that the investment strategy will focus on finding excellent companies with "international competitiveness" in the medical innovation sector, believing that the medical industry will continue to show a positive trend in the latter half of 2025 [2] Fund Valuation - As of June 30, 2025, the fund's weighted average price-to-earnings ratio (TTM) was approximately 59.29 times, compared to the industry average of 120.96 times; the weighted average price-to-book ratio (LF) was about 3.66 times, against an industry average of 4.07 times; and the weighted average price-to-sales ratio (TTM) was around 5.64 times, while the industry average was 6.52 times, indicating that all three valuation metrics are below the industry average [10] Growth Metrics - For the first half of 2025, the weighted revenue growth rate (TTM) of the stocks held by the fund was 0.03%, while the weighted net profit growth rate (TTM) was -0.1%, and the weighted annualized return on equity was 0.06% [15] Fund Size and Shareholder Composition - As of June 30, 2025, the fund's total size was 10.4748 million yuan, with 87 holders collectively owning 12.6316 million shares; management employees held 372,100 shares (2.95%), institutions held 79.17%, and individual investors held 20.83% [31][34] Turnover Rate - The fund's turnover rate for the last six months was approximately 221.93% as of June 30, 2025 [37] Top Holdings - As of June 30, 2025, the fund's top ten holdings included companies such as Innovent Biologics, CSPC Pharmaceutical Group, and BeiGene, among others [38]